Relevant bibliographies by topics / Plasmacytoid dendritic cell, metastatic melanoma

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Conference papers

Academic literature on the topic 'Plasmacytoid dendritic cell, metastatic melanoma'

Author: Grafiati
Published: 11 March 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Plasmacytoid dendritic cell, metastatic melanoma.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Plasmacytoid dendritic cell, metastatic melanoma"

1

Monti, Matilde, Raffaella Vescovi, Francesca Consoli, et al. "Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis." Cancers 12, no. 8 (2020): 2085. http://dx.doi.org/10.3390/cancers12082085.

Full text
Abstract:
The introduction of targeted therapies and immunotherapies has significantly improved the outcome of metastatic melanoma (MM) patients. These approaches rely on immune functions for their anti-melanoma response. Plasmacytoid dendritic cells (pDCs) exhibit anti-tumor function by production of effector molecules, type I interferons (I-IFNs), and cytokines. Tissue and blood pDCs result compromised in MM, although these findings are still partially conflicting. This study reports that blood pDCs were dramatically depleted in MM, particularly in patients with high lactate dehydrogenase (LDH) and hi
APA, Harvard, Vancouver, ISO, and other styles
2

Ye, Juan, Herui Wang, Samik Chakraborty, et al. "Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy." International Journal of Molecular Sciences 26, no. 3 (2025): 1340. https://doi.org/10.3390/ijms26031340.

Full text
Abstract:
Metastatic cancer poses significant clinical challenges, necessitating effective immunotherapies with minimal systemic toxicity. Building on prior research demonstrating the rWTC-MBTA vaccine’s ability to inhibit tumor metastasis and growth, this study focuses on its clinical translation by optimizing vaccine composition, dosing regimens, and freezing techniques. The vaccine formula components included three TLR ligands (LTA, Poly I:C, and Resiquimod) and an anti-CD40 antibody, which were tested in melanoma and triple-negative breast cancer (TNBC) models. The formulations were categorized as r
APA, Harvard, Vancouver, ISO, and other styles
3

Gerlini, Gianni, Carmelo Urso, Giulia Mariotti, et al. "Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes." Clinical Immunology 125, no. 2 (2007): 184–93. http://dx.doi.org/10.1016/j.clim.2007.07.018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pashenkov, Mikhail, Gerda Goëss, Christine Wagner, et al. "Phase II Trial of a Toll-Like Receptor 9–Activating Oligonucleotide in Patients With Metastatic Melanoma." Journal of Clinical Oncology 24, no. 36 (2006): 5716–24. http://dx.doi.org/10.1200/jco.2006.07.9129.

Full text
Abstract:
Purpose The recent identification of toll-like receptors (TLRs) and respective ligands allows the evaluation of novel dendritic cell (DC) –activating strategies. Stimulation of TLR9 directly activates human plasmacytoid DCs (PDCs) and indirectly induces potent innate immune responses in preclinical tumor models. We performed an open-label, multicenter, single-arm, phase II pilot trial with a TLR9-stimulating oligodeoxynucleotide in melanoma patients. Patients and Methods Patients with unresectable stage IIIb/c or stage IV melanoma received 6 mg PF-3512676 weekly by subcutaneous injection for 2
APA, Harvard, Vancouver, ISO, and other styles
5

Royal, Richard Eldon, Luis M. Vence, Tara Wray, et al. "A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application." Journal of Clinical Oncology 35, no. 15_suppl (2017): 9582. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9582.

Full text
Abstract:
9582 Background: Toll like receptor (TLR) agonists may enhance vaccination or direct immune activation at the tumor microenvironment. This trial evaluates the biologic and clinical effects of Resiquimod, a TLR 7/8 agonist that can activate both myeloid (mDC, TLR 8) and plasmacytoid (pDC, TLR 7) dendritic cells, in patients with advanced stage melanoma. Methods: Class I HLA-A0201+ subjects with in-transit melanoma metastases or high risk for recurrence were vaccinated weekly with peptide vaccination (class I restricted peptide GP100209-2m and, if HLA-DP4+, also with class II restricted peptide
APA, Harvard, Vancouver, ISO, and other styles
6

Hanks, Brent Allen, Alisha Holtzhausen, Petra Gimpel та ін. "Effect of the loss of the type III TGFβ receptor during tumor progression on tumor microenvironment: Preclinical development of TGFβ inhibition and TGFβ-related biomarkers to enhance immunotherapy efficacy." Journal of Clinical Oncology 30, № 15_suppl (2012): 10563. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10563.

Full text
Abstract:
10563 Background: Overall, the clinical efficacy of tumor immunotherapy has been limited. Our incomplete understanding of the complex interplay between tumors and the immune microenvironment has contributed to these modest outcomes. Our work has revealed that several tumors downregulate the expression of the type III TGFβ receptor (TβRIII) with progression. TβRIII is shed from the cell surface to generate soluble TβRIII (sTβRIII) which is capable of sequestering TGFβ. Methods and Results: Using both breast cancer and melanoma tumor models we have demonstrated that the loss of TβRIII expression
APA, Harvard, Vancouver, ISO, and other styles
7

Wong, Deborah J. L., Aru Panwar, Ari Rosenberg, et al. "CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma." Journal of Clinical Oncology 39, no. 15_suppl (2021): TPS6089. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.tps6089.

Full text
Abstract:
TPS6089 Background: PD-1 blockade ± chemotherapy has recently become a primary systemic therapy recommended by NCCN guidelines for patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). However, most pts still do not respond to treatment, indicating a large unmet need for pts with unresectable disease. CMP-001 is a toll-like receptor 9 (TLR9) agonist comprising a CpG-A oligodeoxynucleotide packaged in a virus-like particle that can induce type I interferon secretion from tumor-associated plasmacytoid dendritic cells, promoting a Th1-like chemokine mili
APA, Harvard, Vancouver, ISO, and other styles
8

Monti, Matilde, Francesca Consoli, Raffaella Vescovi, Mattia Bugatti, and William Vermi. "Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma." Cells 9, no. 2 (2020): 417. http://dx.doi.org/10.3390/cells9020417.

Full text
Abstract:
The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has significantly improved the survival of MM patients. Notably, all these responses are highly dependent on the fitness of the host immune system, including the innate compartment. Among immune cells involved in cancer immunity, properly activated plasmacytoid dendritic cells (pDCs) exert an important role, bridging the innate and adaptive immune res
APA, Harvard, Vancouver, ISO, and other styles
9

Davar, Diwakar, Arivarasan Karunamurthy, Douglas Hartman, et al. "303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A330. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0303.

Full text
Abstract:
BackgroundNeoadjuvant PD-1 blockade produces major pathological responses (MPR) in ~30% of patients (pts) with high-risk resectable melanoma (MEL) with durable relapse-free benefit, and increased circulating activated CD8+ T cells.1 2 CMP-001 is a type A CpG packaged within a virus-like particle that activates tumor-associated plasmacytoid dendritic cells (pDC) via TLR9 inducing type I interferons and anti-tumor CD8+ T cells. CMP-001/pembrolizumab produces durable anti-tumor responses in PD-1 refractory melanoma.3 We previously reported preliminary evidence of efficacy of neoadjuvant IT CMP/Ni
APA, Harvard, Vancouver, ISO, and other styles
10

de Rosa, Francesco, Laura Ridolfi, Laura Fiammenghi, et al. "Dendritic cell vaccination for metastatic melanoma." Melanoma Research 27, no. 4 (2017): 351–57. http://dx.doi.org/10.1097/cmr.0000000000000356.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Plasmacytoid dendritic cell, metastatic melanoma"

1

VESCOVI, Raffaella. "Characterization of plasmacytoid dendritic cells compartment in advanced melanoma." Doctoral thesis, 2016. http://hdl.handle.net/11562/939213.

Full text
Abstract:
Le cellule dendritiche plasmacitoidi (PDC) sono una rara sottopopolazione dell’immunità innata. Dopo lo sviluppo vengono rilasciate dal midollo osseo e migrano verso gli organi linfoidi secondari. A seguito dell’attivazione dei TLR7/9, le PDC possono svolgere un’attività antitumorale mediante la produzione di IFN-α che influenza negativamente la proliferazione delle cellule tumorali, la linfoangiogenesi tumorale, lo sviluppo delle metastasi e aumenta la citotossicità tumorale. Il segnale autocrino di IFNα/β attivato nelle PDC modula una serie di geni indotti da I-IFN come CXCL-10/IP-10, chemoc
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Plasmacytoid dendritic cell, metastatic melanoma"

1

Dillman, Robert O., Andrew N. Cornforth, Carol DePriest, et al. "Abstract 3703: Randomized trial of autologous dendritic cell vs tumor cell vaccines in patients with metastatic melanoma." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3703.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Carreno, Beatriz M., Michelle Becker-Hapak, Alexander Huang, et al. "Abstract LB-157: IL-12p70 producing dendritic cell vaccine elicits Tc1 polarized T cells and extends time to progression in metastatic melanoma." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-lb-157.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Cornforth, Andrew N., Gary Fogel, Denysha Carbonell, and Robert O. Dillman. "Abstract 4845: Microarray analysis of melanoma autologous tumor cell lines used as the source of tumor associated antigens in patient-specific dendritic cell immunotherapy phase II trial in patients with metastatic melanoma." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4845.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dillman, Robert O., Gabriel I. Nistor, Aleksandra J. Poole, and Andrew N. Cornforth. "Abstract 1357: Serum levels of programmed cell death molecule-1 (PD-1) as a biomarker in metastatic melanoma patients randomized for treatment with autologous dendritic cell or tumor cell vaccines." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1357.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dillman, Robert O., Gabriel I. Nistor, Aleksandra J. Poole, and Andrew N. Cornforth. "Abstract 1357: Serum levels of programmed cell death molecule-1 (PD-1) as a biomarker in metastatic melanoma patients randomized for treatment with autologous dendritic cell or tumor cell vaccines." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1357.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Britting, Sabine, Niels Schaft, Jan Dörrie, et al. "Abstract 1585: Primary and metastatic uveal melanoma cell lines express MelanA that can be used as a target antigen for transfection of mature dendritic cells." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1585.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Chick, Robert Connor, Annelies T. Hickerson, Guy Travis Clifton, et al. "Abstract 6536: Safety and efficacy of autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccination in combination with systemic therapies in patients with metastatic melanoma." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-6536.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Plasmacytoid dendritic cell, metastatic melanoma' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography